The estimated Net Worth of David F Drohan is at least $3.23 Millón dollars as of 3 May 2004. David Drohan owns over 25,000 units of Baxter International stock worth over $2,429,988 and over the last 21 years David sold BAX stock worth over $798,750.
David has made over 1 trades of the Baxter International stock since 2004, according to the Form 4 filled with the SEC. Most recently David sold 25,000 units of BAX stock worth $798,750 on 3 May 2004.
The largest trade David's ever made was selling 25,000 units of Baxter International stock on 3 May 2004 worth over $798,750. On average, David trades about 12,500 units every 0 days since 2003. As of 3 May 2004 David still owns at least 61,879 units of Baxter International stock.
You can see the complete history of David Drohan stock trades at the bottom of the page.
David's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD, IL, 60015.
Over the last 21 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney y Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: